New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

SAN JOSE, Antique (PIA) — The municipality of Tobias Fornier recently activated its Barangay Information Officers (BIO) ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay ...

Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei ...

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of ...